Piotr Alvarez lays out a three-stage outlook for AI in peptide method development, and the panel argues scientists keep the final judgment as conjugates get more complex.
Recap by typeshit. Full story at LCGC International.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
Takashi Miki tells HCPLive the effect didn't need immune iNKT cells, and suggests pairing GLP-1 drugs with PPARα activators for fatty liver disease.
A projection framing weight loss drugs as a growing slice of American healthcare spending. Thin on detail beyond the market forecast.
Loading…